Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention
Felipe V. Gomes, Anthony A. Grace
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 9, pp. 4467-4467
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Negative symptoms in schizophrenia: Newly emerging measurements, pathways, and treatments
Stephen R. Marder, Daniel Umbricht
Schizophrenia Research (2023) Vol. 258, pp. 71-77
Open Access | Times Cited: 44
The excitatory-inhibitory balance as a target for the development of novel drugs to treat schizophrenia
Daniela L. Uliana, João Roberto Lisboa, Felipe V. Gomes, et al.
Biochemical Pharmacology (2024) Vol. 228, pp. 116298-116298
Closed Access | Times Cited: 18
Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic
Samantha E. Yohn, Peter J. Weiden, Christian C. Felder, et al.
Trends in Pharmacological Sciences (2022) Vol. 43, Iss. 12, pp. 1098-1112
Open Access | Times Cited: 64
Mitochondrial, exosomal miR137-COX6A2 and gamma synchrony as biomarkers of parvalbumin interneurons, psychopathology, and neurocognition in schizophrenia
Inès Khadimallah, Raoul Jenni, Jan-Harry Cabungcal, et al.
Molecular Psychiatry (2021) Vol. 27, Iss. 2, pp. 1192-1204
Open Access | Times Cited: 61
Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders
Els F. Halff, Grazia Rutigliano, Anna Garcia-Hidalgo, et al.
Trends in Neurosciences (2022) Vol. 46, Iss. 1, pp. 60-74
Open Access | Times Cited: 61
New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics
Maria Lobo, Thomas Whitehurst, Stephen Kaar, et al.
Neuroscience & Biobehavioral Reviews (2021) Vol. 132, pp. 324-361
Open Access | Times Cited: 57
Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
Michael Davidson, Jay Saoud, Corinne Staner, et al.
Schizophrenia Bulletin (2022) Vol. 48, Iss. 3, pp. 609-619
Open Access | Times Cited: 46
Antisocial personality disorder:Failure to balance excitation/inhibition?
Klaus‐Peter Lesch, Nikita Gorbunov
Neuropharmacology (2025), pp. 110321-110321
Closed Access | Times Cited: 1
Prefrontal and Hippocampal Parvalbumin Interneurons in Animal Models for Schizophrenia: A Systematic Review and Meta-analysis
Thamyris Santos‐Silva, Débora dos Santos Fabris, Cilene Lino de Oliveira, et al.
Schizophrenia Bulletin (2023) Vol. 50, Iss. 1, pp. 210-223
Open Access | Times Cited: 17
Perineuronal nets as regulators of parvalbumin interneuron function: Factors implicated in their formation and degradation
Thamyris Santos‐Silva, Débora Akemi Endo Colodete, João Roberto Fernandes Lisboa, et al.
Basic & Clinical Pharmacology & Toxicology (2024) Vol. 134, Iss. 5, pp. 614-628
Closed Access | Times Cited: 8
Mood and behavior regulation: interaction of lithium and dopaminergic system
Marjan Mohamadian, Hamed Fallah, Zahra Ghofrani-Jahromi, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2023) Vol. 396, Iss. 7, pp. 1339-1359
Closed Access | Times Cited: 15
Mapping Brain Synergy Dysfunction in Schizophrenia: Understanding Individual Differences and Underlying Molecular Mechanisms
Chaoyue Ding, Ang Li, Sangma Xie, et al.
Advanced Science (2024) Vol. 11, Iss. 32
Open Access | Times Cited: 4
Schizophrenia: Antipsychotics and drug development
Gary Remington, Margaret Hahn, Sri Mahavir Agarwal, et al.
Behavioural Brain Research (2021) Vol. 414, pp. 113507-113507
Closed Access | Times Cited: 25
Distinct Effects of Olanzapine Depot Treatment on Behavior and Muscarinic M1 Receptor Expression in the Triple‐Hit Wisket Rat Model of Schizophrenia
Gyöngyi Horváth, Eszter Ducza, Leatitia Gabriella Adlan, et al.
Genes Brain & Behavior (2025) Vol. 24, Iss. 1
Open Access
Glutamate and Proton MR Spectroscopy in Schizophrenia
Teruki Koizumi, Ariel Graff‐Guerrero
Neuromethods (2025), pp. 159-173
Closed Access
TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner
Sung Min Yang, Ayan Ghoshal, Jeffrey M. Hubbard, et al.
Neuropsychopharmacology (2023) Vol. 49, Iss. 7, pp. 1091-1103
Open Access | Times Cited: 9
Grey matter volume loss in Parkinson’s disease psychosis and its relationship with serotonergic gene expression: A meta-analysis
Sara Pisani, Brandon Gunasekera, Yining Lu, et al.
Neuroscience & Biobehavioral Reviews (2023) Vol. 147, pp. 105081-105081
Open Access | Times Cited: 8
Voltage-gated potassium channels as a potential therapeutic target for the treatment of neurological and psychiatric disorders
Isabel E Faulkner, Rachael Z Pajak, Michael Harte, et al.
Frontiers in Cellular Neuroscience (2024) Vol. 18
Open Access | Times Cited: 3
Levetiracetam Attenuates Adolescent Stress-induced Behavioral and Electrophysiological Changes Associated With Schizophrenia in Adult Rats
Andreza M Cavichioli, Thamyris Santos‐Silva, Anthony A. Grace, et al.
Schizophrenia Bulletin (2022) Vol. 49, Iss. 1, pp. 68-77
Open Access | Times Cited: 14
Diurnal Alterations in Gene Expression Across Striatal Subregions in Psychosis
Kyle D. Ketchesin, Wei Zong, Mariah A. Hildebrand, et al.
Biological Psychiatry (2022) Vol. 93, Iss. 2, pp. 137-148
Open Access | Times Cited: 14
Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia
Jonathan M. Meyer, Christoph U. Correll
CNS Drugs (2023) Vol. 37, Iss. 7, pp. 545-570
Open Access | Times Cited: 8
Potassium channel modulators and schizophrenia: an overview of investigational drugs
Meghan Musselman, Eric Huynh, Rachana Kelshikar, et al.
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 6, pp. 471-477
Closed Access | Times Cited: 7
Global Neuropsychopharmacological Prescription Trends in Adults with Schizophrenia, Clinical Correlates and Implications for Practice: A Scoping Review
Jiangbo Ying, Qian Hui Chew, Yuxi Wang, et al.
Brain Sciences (2023) Vol. 14, Iss. 1, pp. 6-6
Open Access | Times Cited: 7
Exploring the molecular targets of fingolimod and siponimod for treating the impaired cognition of schizophrenia using network pharmacology and molecular docking
Chao Li, Chuanjun Zhuo, Xiaoyan Ma, et al.
Schizophrenia (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 2
Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions
Joshua T. Kantrowitz
CNS Drugs (2021) Vol. 35, Iss. 11, pp. 1153-1161
Closed Access | Times Cited: 13
Page 1 - Next Page

Scroll to top